Project Grant R56HL169285
Award Date
9/13/24
Completion Date
8/31/25
Dollars Obligated
$654K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research supports research to investigate the role of reduced hypusination of the translation factor EIF5A in the development of heart failure with preserved ejection fraction (HFpEF). The $126,387 award to The Johns Hopkins University, granted on June 15, 2025, aims to study how depressed EIF5A hypusination impairs the translation of ubiquitin precursors and...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $773,446 to The Washington University to conduct research focused on understanding the role of the matricellular protein thrombospondin-1 (TSP1) in stabilizing the provisional extracellular matrix and regulating cellular responses in the injured lung. The research aims to: 1) Determine whether platelet/megakaryocyte-derived TSP1 regulates neutrophil activation and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $699,133 in funding to the University of California, Los Angeles (UCLA) to conduct research on the epigenetic regulation of heart failure with preserved ejection fraction (HFPEF). The key goals are to reveal molecular insights into the actions of SGLT2 inhibitor and GLP1 agonist drugs across multiple organs, identify novel...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $500,089.80 to the University of Pittsburgh to investigate the role of macrophages in heart failure with preserved ejection fraction (HFPEF). The goal is to uncover the mechanisms by which inflammatory macrophages mediate cardiac remodeling and diastolic dysfunction in HFPEF, a complex condition affecting ~50% of heart failure cases....
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $507,096.00 to Wake Forest University Health Sciences to conduct research on the role of mitochondrial calcium signaling in heart failure with preserved ejection fraction (HFPEF). The key objectives are to: Characterize heart cell-specific mitochondrial calcium signaling and functions in HFPEF mouse models, 2) Evaluate the effects...
This federal Project Grant award of $2,249,307, provided by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), aims to study the premature maturation arrest of pluripotent-derived cardiomyocytes (PSC-CMs) and develop strategies to overcome this issue. The project will leverage a high-resolution single cell transcriptome map of endogenous cardiomyocyte maturation to identify a critical gene regulatory network underlying the maturation failure in PSC-CMs....
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research into the role of the long non-coding RNA SALTE1 in vascular aging and heart failure with preserved ejection fraction (HFPEF). The $708,266 award to The General Hospital Corporation (doing business as Massachusetts General Hospital) will fund a 4-year research project to determine the role of SALTE1 in vascular aging and HFPEF, and examine the underlying...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program provides $735,838 to the University of Arizona to conduct research on the role of hexokinase 1 (HK1) mitochondrial binding in cardiac endothelial cell function and the development of heart failure with preserved ejection fraction (HFpEF). The research aims to determine if HK1 mitochondrial dislocation leads to increased protein O-GlcNAcylation,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute, Inc. to investigate the genetic basis and underlying mechanisms of heart failure. The research leverages high-throughput cellular analysis techniques, including cell painting and Perturb-seq, to functionally characterize genetic variants associated with heart failure risk. The goal is to rapidly...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $125,250 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct a 2-year research study on the role of the cytokine FAM3D in heart failure. The principal investigator, Dr. James Rhee, will lead a team of scientists to investigate how FAM3D regulates cardiac fibroblasts and the lymphatic system to limit inflammation and...